Introduction
Natural killer (NK) cells are important early innate effector cells of the antiviral immune response, as they can not only directly lyse virally infected cells but also indirectly regulate innate and adaptive immune responses via cytokine production and crosstalk with dendritic cells [1] [2] [3] [4] . NK cell activity is determined by the interaction of inhibitory and activating NK cell receptors with ligands expressed on target cells. Killer cell immunoglobulin-like receptors (KIRs) are one of the major receptor families expressed on NK cells and interact with human leukocyte antigen (HLA) class I ligands. Several studies have suggested that KIR-expressing NK cells might play an important role in the control of HIV infection [5] [6] [7] [8] [9] .
Characterization of the interactions between KIRs and their HLA ligands by crystal structure analysis has shown that KIRs directly interact not just with the a1 and a2 domains of HLA class I ligands but also with the bound peptide, although to a lesser extent than T-cell receptors [10] [11] [12] [13] [14] . KIRs therefore recognize their cognate HLA class I ligands in a peptide-dependent manner [10, [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] . Charge complementarity dominates KIR-HLA interactions, and mutations in presented peptides can alter the interface salt bridges to either diminish or promote KIR-HLA binding [15] [16] [17] [18] [19] 25, 26] . In particular, variations in C-terminal residues of HLA class I-bound peptides can modulate KIR engagement and, ultimately, NK cell responsiveness to target cells [10, 14, [16] [17] [18] [22] [23] [24] [25] [26] .
In this study, we investigated the consequences of sequence variations in HLA-C Ã 03:04-presented HIV-1 p24 Gag epitopes on binding of KIR2DL2. KIR2DL2 is an inhibitory KIR that binds to HLA-C group 1 ligands and has a population frequency of nearly 50% [27] . HLA-C expression is believed to influence HIV-1 disease progression, as it is resistant to downregulation by HIV-1 Nef (unlike HLA-A and HLA-B) [28] , and higher expression levels have been associated with improved control of HIV-1 infection [29] [30] [31] . The protective effect of HLA-C expression might in part rely on its peptidedependent interaction with KIRþ NK cells. Here, we identified several HIV-1 epitopes, as well as naturally occurring variants, which alter KIR2DL2 binding to HLA-C Ã 03:04 and modulate primary KIR2DL2þ NK cell function in a sequence-dependent manner.
Materials and methods

Cells
The 721.220 cells (referred to as 220 cells hereafter) were stably transducted with HLA-C Ã 03:04 as previously described for 721.221 cells [32] and were used in the initial screening for HLA-C Ã 03:04 stabilizing peptides. The 220 cells do not express HLA-A and HLA-B but retain partial expression of HLA-C Ã 01:02 [33] . Furthermore, 220 cells lack functional tapasin, which impedes expression of nonclassical HLA class I and impairs loading of peptides onto classical HLA class I [33, 34] . A 721.221 cell line stably transduced with herpes simplex virus type 1 ICP47 (kindly provided by Emmanuel J.H.J. Wiertz, Department of Medical Microbiology, University Medical Center, Utrecht, the Netherlands) and HLA-C Ã 03:04 (referred to as 221-ICP47-C Ã 03:04 hereafter) were used in all further experiments. The 221 cells do not express HLA-A, HLA-B or HLA-C, and the transduced ICP47 inhibits TAP function and thus impairs the loading of peptides onto HLA class I. Both cell lines were cultured in selection medium [RPMI medium 1640 (Sigma-Aldrich, St Louis, Missouri, USA) supplemented with 10% heat-inactivated foetal calf serum (FCS; Sigma-Aldrich), 2500 U/ml penicillin, 2500 mg/ml streptomycin, 100 mmol/l L-Glutamine (Cellgro, Herndon, Virginia, USA) and 1 mg/ml puromycin] at 378C under 5% CO 2 .
For studies of primary NK cell function, six healthy HIV-1 negative individuals were recruited at Massachusetts General Hospital (MGH, Boston, Massachusetts, USA). The study was approved by Partners Institutional Review Board (IRB) and each individual gave informed consent for participation.
Human leukocyte antigen-C stabilization assay A total of 222 10-mer peptides overlapping by nine amino acids and spanning the entire HIV-1 p24 Gag consensus sequence were used to identify HIV-1 peptides that stabilize HLA-C Ã 03:04 expression. A total of 2 Â 10 5 220-C Ã 03:04 cells were coincubated with these overlapping peptides (OLPs) in nonsupplemented RPMI for 30 h at 378C. As controls, 220-C Ã 03:04 cells were cultured in the absence of peptide or with the previously described HLA-C Ã 03:04-binding self-peptides, GAVDPLLAL (GAL) and GAVDPLLKL (GKL) [10] . To detect HLA-C stabilization, peptide-pulsed 220-C Ã 03:04 cells were stained with mouse antihuman HLA-C specific antibody (DT9) and secondary antibody antimouse IgG-PE (Sigma-Aldrich). After staining, cells were fixed in 4% paraformaldehyde and analysed by flow cytometry. HLA-C Ã 03:04-binding peptides were reconfirmed using 221-ICP47-C Ã 03:04 cells. Briefly, 221-ICP47-C Ã 03:04 cells were coincubated with HIV-1 and control peptides (100 mmol/l) in nonsupplemented RPMI for 20 h at 268C. HLA stabilization was measured using the pan-HLA antibody (anti-HLA-A/B/C, clone W6/32; BioLegend, San Diego, California, USA).
Epitope prediction tools
To screen for potential HLA-C Ã 03:04-binding epitopes among HIV-1 p24 Gag, the entire HIV-1 p24 Gag consensus sequence was entered into the NetMHCpan 2.4 HLArestrictor tool program (http://www.cbs.dtu. dk/services/HLArestrictor/). Binding prediction scores were calculated as 1/NetMHCpan percentile rank. If the HLA-C Ã 03:04 stabilizing 10-mer was not among the prediction results, we listed the percentile rank score of the corresponding 8-mer or 9-mer variant instead. Standard recommended threshold settings were used. In search of previously described HLA-C Ã 03 restricted HIV-1 p24 Gag epitopes, the Los Alamos CTL epitope database (http://www.hiv.lanl.gov/content/immunology/ ctl_search) was employed. To check for sequence variations at P7, P8, and P9 among identified HLA-C Ã 03:04presented epitopes, the Los Alamos HIV-1 Sequence Database QuickAlign tool (http://www.hiv.lanl.gov/ content/sequence/QUICK_ALIGN/QuickAlign.html), which includes amino acid sequences of more than 3500 described HIV-1 variants, was used.
KIR2DL2 binding assay
The peptides, and their naturally occurring variants, which resulted in strong HLA-C stabilization in 220-C Ã 03:04 and 221-ICP47-C Ã 03:04 cells were tested for binding of KIR2DL2 to peptide-stabilized HLA-C Ã 03:04 on 221-ICP47-C Ã 03:04 cells. After incubating 221-ICP47-C Ã 03:04 cells with the candidate peptides, cells were stained with KIR2DL2-Fc (recombinant human KIR2DL2-Fc/CD158b1 chimera; R&D Systems, Minneapolis, Minnesota, USA) and antihuman Fc antibody (PE conjugated IgG Goat Anti-Human pAb; Invitrogen Life Technologies, Carlsbad, California, USA). After staining, cells were washed, fixed in 4% paraformaldehyde and then analysed by flow cytometry.
Natural killer cell degranulation assay NK cell degranulation assays were performed with freshly isolated and purified NK cells from six healthy individuals of which two were KIR2DL2þ/C1þ, three were KIR2DL2-3þ/C1þ, and one was KIR2DL2-3þ/C1-2þ. Primary NK cells were isolated by incubating whole blood with RosetteSep NK cell enrichment cocktail (Stem Cell Technologies, Vancouver, Canada) and performing a Histopaque-1077 (Sigma-Aldrich) density gradient centrifugation. NK cells were subsequently incubated overnight in RPMI medium 1640 (Sigma-Aldrich) supplemented with 10% heat-inactivated FCS (Sigma-Aldrich), 2500 U/ml penicillin, 2500 mg/ml streptomycin, 100 mmol/l L-glutamine (Corning Cellgro, Manassas, Virginia, USA) and 1.0 ng/ml interleukin (IL)-15 (Corning Cellgro). Next, NK cells (1 Â 10 5 ) were coincubated with peptide-pulsed 221-ICP47-C Ã 03:04 cells (5 Â 10 5 ) at an effector-target ratio of 1 : 5 in RPMI containing antihuman CD107a-PE-Cy7 (12.5 ml/ml). Cells were incubated for 30 min at 268C in 5% CO 2 , after which monensin (1.5 ml/ml, BD GolgiStop; BD Biosciences, Franklin Lakes, New Jersey, USA) was added, followed by an additional 5 h of incubation at 268C in 5% CO 2 . Cells were stained with anti-CD3-PB, anti-CD16-BV785, anti-CD56-BV605, anti-CD14/19-BV510, anti-KIR2DL2/3-PE and anti-KIR2DL3-APC, washed, fixed with 4% paraformaldehyde and analysed by flow cytometry.
Data acquisition and analysis
Flow cytometry data were acquired using BD 3 Laser LSRII (BD Biosciences) and analysed using FlowJo software version 9.4.4 (Tree Star, Inc., Ashland, Oregon, USA). For statistical analysis, GraphPad Prism 5.0d (GraphPad Software Inc., La Jolla, California, USA) was used. HLA stabilization values are presented as relative mean AE SEM. Relative mean was calculated by dividing the mean fluorescence intensity (MFI) of a given OLP by the MFI of the negative control 'no peptide' in the respective assay. KIR2DL2 binding is presented in percentages KIR2DL2-Fcþ cells and NK cell degranulation values are expressed as normalized degranulation. Normalized degranulation was calculated by dividing the percentage CD107aþ cells of a given sample by the percentage CD107aþ cells of negative control sample 'GKL' after reduction of background CD107aþ expression. Statistical comparison between groups was performed using repeated-measures analysis of variance (ANOVA).
Results
Several HIV-1 p24 Gag-derived peptides stabilize human leukocyte antigen-C expression on 220-C M 03:04 cells In order to investigate whether HIV-1 peptides presented by HLA-C Ã 03:04 can impact the binding of KIR2DL2, we initially screened for HIV-1 p24 Gag peptides that stabilized HLA-C expression on HLA-C Ã 03:04-expressing tapasin-deficient 220 cells. We used 222 10-mer peptides overlapped by nine amino acids that spanned the entire HIV-1 p24 Gag consensus sequence (based on sequences published in the Los Alamos database http:// www.hiv.lanl.gov/content/index, see Supplemental Table 1 , http://links.lww.com/QAD/A512). Two previously described HLA-C Ã 03-presented self-peptides GAL (GAVDPLLAL) and GKL (GAVDPLLKL) were also included as positive controls (see Supplemental Figure 1 , http://links.lww.com/QAD/A512) [10] . Table 1 presents the seven OLPs that induced strong HLA-C stabilization (i.e. high DT9 fluorescence intensity) on 220-C Ã 03:04 cells, which were also confirmed in 221-ICP47-C Ã 03:04 cells. Given that nine amino acid long peptides have been described to have the optimal length for HLA-C Ã 03:04 binding [19] , we investigated whether 9-mer peptides contained within these seven 10-mers could stabilize HLA-C Ã 03:04 more efficiently. In most cases, one of the respective 9-mer peptides stabilized HLA-C Ã 03:04 expression more so than its 10-mer counterpart (Fig. 1a ). Thus, in subsequent KIR2DL2-Fc-binding experiments and functional assays, we used the most strongly stabilizing peptides.
From the peptide screening in 220-C Ã 03:04 cells, an HLA-C stabilization (DT9) score was generated and calculated as the median DT9 fluorescence intensity of a given OLP divided by the median DT9 fluorescence intensity of all 222 OLPs in an average of four independent experiments. In addition, to verify whether the identified HLA-C stabilizing peptides contained HLA-C Ã 03 binding motifs or previously described HLA-C Ã 03-restricted epitopes, we used the NetMHCpan 2.4 HLArestrictor tool (http://www.cbs.dtu.dk/services/ HLArestrictor/) and the Los Alamos CTL/CD8 T cell epitope database (http://www.hiv.lanl.gov/content/ immunology/ctl_search). All seven selected peptides that stabilized HLA-C expression were also predicted to serve as HLA-C Ã 03:04 binders by the NetMHCpan 2.4 HLArestrictor tool (Table 1) , and the HLArestrictor tool percentile rank scores of the seven selected optimal epitopes differed significantly from the scores of the 215 nonbinders (Mann-Whitney test, P < 0.0001, Fig. 1b ). However, some of the peptides that did not show any HLA-C Ã 03:04 binding experimentally still scored well using the HLArestrictor tool. We furthermore observed a highly significant but moderate correlation between percentile rank scores of all 222 OLPs and our HLA-C stabilization assay values (Spearmans r-value 0.24, P < 0.0001, Fig. 1c ). Three of the seven identified HLA-C Ã 03:04-binding peptides had also previously been described in the Los Alamos database to contain HLA-C Ã 03:04-restricted CTL epitopes; OLP11 (Gag140-152 and Gag145-152) [35, 36] , OLP34 (Gag167-175) [37] and OLP163 (Gag295-304) [38] [39] [40] [41] [42] (Table 1) . However, two other previously described HLA-C Ã 03restricted CTL epitopes, TLRAEQATQD (Gag303-312) [43] and KALGPAATL (Gag335-343) [37] , were not identified using our stabilization assay, probably due to sequence differences between the described epitope and the epitope used in our assay (TLRAEQASQE versus TLRAEQATQD and KALGPAATLE versus KALG-PAATL) [37, 43] . In conclusion, we identified seven 1402 AIDS 2014, Vol 28 No 10 The lower the NetMHCpan percentile rank score, the higher the predicted affinity of the peptide for HLA-C M 03:04.
peptides within HIV-1 p24 Gag that resulted in strong HLA-C stabilization on both 220-C Ã 03:04 and 221-ICP47-C Ã 03:04 cells, and these seven peptides were subsequently selected for KIR2DL2 binding assays.
A subset of HLA-C M 03:04-restricted HIV-1 epitopes allows for KIR2DL2 binding To assess the influence that HLA-C Ã 03:04-bound HIV-1 epitopes have on KIR2DL2 binding to HLA-C Ã 03:04, we stained peptide-pulsed 221-ICP47-C Ã 03:04 cells with KIR2DL2-Fc. 221-ICP47-C Ã 03:04 cells were pulsed with no peptide, the HLA-C Ã 03:04-presented control peptides GAVDPLLAL (GAL) or GAVDPLLKL (GKL), or the seven HIV-1 p24 Gag peptides (consensus sequence peptides of Table 1 ). GAL and GKL served as a positive and a negative control, respectively, for KIR2DL2 binding, given that it has previously been shown that GAL allows for KIR2DL2 binding to HLA-C Ã 03 whereas GKL abrogates it (see Fig. 2a for representative histograms) [10] . The results of repeated (N ¼ 3) KIR2DL2 binding analyses are summarized in Fig. 2b . Three out of the seven tested HLA-C Ã 03:04binding epitopes, OLP11 (Gag144-152), OLP30 (Gag163-171) and OLP163 (Gag295-304) allowed for similar or stronger KIR2DL2-Fc binding when than the positive control peptide GAL (Fig. 2b) . The seven selected peptides were further tested for their ability to engage KIR2DL3-Fc to HLA-C Ã 03:04, given that KIR2DL3 and KIR2DL2 are alleles of each other and are very similar in sequence and binding properties. Indeed, KIR2DL3-Fc was engaged by the same three HLA-C Ã 03:04-bound peptides as KIR2DL2-Fc, and at similar levels (Fig. 2c ).
Taken together, three out of seven HLA-C Ã 03:04presented epitopes derived from the HIV-1 p24 consensus sequence facilitated KIR2DL2-Fc and KIR2DL3-Fc binding, although the remaining four peptides did not allow for binding of either KIR2DL2-Fc or KIR2DL3-Fc to peptide-pulsed 221-ICP47-C Ã 03:04 cells.
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-GAL GKL 10 9-II 10 9-I 9-II 10 9-I 9-II 10 9-I 9-II 10 9-I 9-II 10 9-I 9-II 10 9-I 9-II 0 Table 1 ) to the binding prediction scores of the 215 OLPs we assigned to be nonbinders (P < 0.0001). (c) Binding prediction scores plotted against DT9 HLA-C stabilization values for all 222 OLPs. The encircled dots represent the seven selected optimal epitopes. All nonencircled dots represent the peptides we assigned to be nonbinders based on HLA-C stabilization results. Correlation statistics: P < 0.0001, r-value 0.24. Point mutations in HLA-bound HIV-1 epitopes result in enhanced KIR2DL2 binding to HLA-C M 03:04 Functional studies of KIR2DL2/HLA-C Ã 03:04 interactions and the crystal structure of KIR2DL2/HLA-C Ã 03:04 have suggested that binding of KIR2DL2 to HLA-C Ã 03:04 is affected by amino acid residues in positions 7 and 8 (P7, P8) of the HLA-bound 9-mer epitope [10, 19] . We therefore screened the seven selected epitopes for naturally occurring sequence variations, using the Los Alamos HIV-1 Sequence Database QuickAlign tool that includes amino acid sequences of more than 3500 described HIV-1 variants (http://www.hiv.lanl.gov/content/index). In addition to sequence variations in position 7 (P7) and position 8 (P8) of the epitopes, we also assessed variations at position 9 (P9), as for two peptides we used the better HLA-C Ã 03:04-stabilizing 10-mer epitope instead of the corresponding 9-mers. Three of the seven HLA-C Ã 03:04-presented epitopes exhibited variation at positions 7, 8, and/or 9. Table 1 summarizes the respective variant epitopes as well as the frequency of these sequence polymorphisms (%) within the more than 3500 studied HIV-1 sequences contained in the Los Alamos Database. The consensus sequence epitopes and their variants summarized in Table 1 did not significantly differ in their ability to stabilize HLA-C Ã 03:04 expression on transduced 221-ICP47-C Ã 03:04 cells (Supplemental Figure 1 , http:// links.lww.com/QAD/A512). Subsequent KIR2DL2-Fc binding assays were performed to assess the impact of the aforementioned variant epitopes on KIR2DL2 binding (Fig. 2d ). Variant peptide OLP30-7I and all OLP34 variants allowed for less or insignificant binding when compared with the respective consensus sequence peptide variant (Fig. 2d) . In contrast, the variant epitopes OLP163-9A, OLP163-9I and especially OLP163-9V led to enhanced and significant engagement of KIR2DL2-Fc compared with the OLP163 consensus sequence (OLP163-CSeq). Altogether, we identified three (OLP11, OLP30 and OLP163) optimal HIV-1 p24 Gag HLA-C epitopes that possess major and minor naturally occurring variants that led to significant KIR2DL2 engagement to HLA-C Ã 03:04.
KIR2DL2-Fc-PE
HLA-C M 03:04-bound KIR2DL2-engaging HIV-1 epitopes can inhibit primary natural killer cell function To determine the functional relevance of HIV-1 derived epitopes that enabled KIR2DL2 binding, NK cell degranulation assays were performed using primary NK cells derived from KIR2DL2þ individuals. Freshly isolated and purified NK cells were cocultured with peptide-pulsed 221-ICP47-C Ã 03:04 target cells. Target cells loaded with the positive control peptide GAL, OLP11 and OLP30, which potently engaged KIR2DL2-Fc, significantly inhibited KIR2DL2þ NK cell degranulation, whereas target cells loaded with negative control peptide GKL did not (Fig. 3a,b) . In contrast, the function of KIR2DL2-NK cells from the same individuals was not affected by the presence or absence of these peptides (Fig. 3a,c) . In conclusion, the HIV-1 p24 Gag peptides OLP11 and OLP30 did not only strongly engage KIR2DL2-Fc but also suppressed primary KIR2DL2þ NK cell function when presented by HLA-C Ã 03:04, demonstrating a functional consequence of modulated KIR2DL2/HLA-C Ã 03:04 interactions for NK cells.
Discussion
Binding of KIR to HLA class I regulates NK cell function in a manner that can be modulated by HLA-bound peptides. In order to investigate the influence of sequence variations in HLA-C Ã 03:04-binding HIV-1 p24 Gag epitopes on KIR2DL2 binding, we first screened the entire HIV-1 p24 Gag sequence for epitopes that stabilized HLA-C expression on HLA-C Ã 03 : 04-expressing 220 cells, and then assessed KIR2DL2 binding to HLA-C Ã 03:04 presenting the selected optimal epitopes. Three out of seven consensus sequence derived HLA-C Ã 03:04-binding epitopes allowed for KIR2DL2-Fc binding and similarly engaged KIR2DL3. Subsequent testing of naturally occurring peptide variants of the identified HLA-C Ã 03:04-binding HIV-1 epitopes revealed several additional KIR2DL2-Fc-engaging epitopes. Furthermore, engagement of KIR2DL2 by these HLA-C Ã 03:04-presented HIV-1 peptides inhibited primary KIR2DL2þ NK cell function in vitro. Altogether, we identified several major and minor circulating variants of HLA-C Ã 03:04-binding HIV-1 p24 Gag epitopes that engage KIR2DL2 and consequently inhibit KIR2DL2þ NK cell function.
In order to identify peptides within HIV-1 that bind to HLA-C Ã 03:04 for subsequent assessment of KIR2DL2 binding, we initially performed HLA-C-stabilization assays using HLA-C Ã 03:04-expressing, tapasin-deficient 220 cells, and identified seven epitopes that led to the strong HLA-C-specific DT9 staining, which reflects epitope binding to HLA-C. The optimal HLA-C Ã 03:04binding motif, X-A-(Q/A)-D-X-X-X-X-L was not present in every selected epitope. However, five of the seven selected 10mer epitopes contained a Leucine (L) towards the C-terminal end with a relatively small residue in the prior amino acid position, which is in line with the described binding motif for HLA-C Ã 03:04 and previous studies [19] . Furthermore, we validated our experimentally determined HLA-C Ã 03:04 binding results with an online prediction tool and a comparison to HIV-1 CTL epitope databases. All selected epitopes were predicted to serve as HLA-C Ã 03:04 binders and predicted binding scores of the identified epitopes differed significantly from the 215 peptides that resulted in no or insignificant stabilization of HLA-C. Furthermore, three previously described p24 Gag HLA-C Ã 03(:04)-restricted CTL epitopes were contained within the epitopes we identified, that is OLP11, 34 and 163 [35] [36] [37] [38] [39] [40] [41] [42] . Further testing of the HLA-C Ã 03:04-stabilizing capacities of 9mers within the selected 10-mers showed a preference of HLA-C Ã 03:04 for 9 amino acid long peptide, also in concordance with previous studies [19] . Taken together, we identified several novel HLA-C Ã 03:04-presented epitopes within HIV-1 p24 Gag, which were subsequently assessed to determine their impact on KIR2DL2 binding to HLA-C Ã 03:04.
The interaction between KIR and HLA class I can be modulated by the sequence of the HLA-presented peptides. Consistent with this observation, we show that naturally occurring sequence variations in HIV-1 p24 Gag can promote KIR2DL2 binding to HLA-C Ã 03:04, and identified an epitope (Gag295-304) for which the minor circulating variants allowed for enhanced binding of KIR2DL2 compared with the HIV-1 clade B consensus sequence epitope. In line with previously described structural data [10, 14] , we also demonstrate that the residues towards the C-terminal end of the HLA class I bound peptide are crucial in modulation of KIR2DL2 binding. Yet, we could not reveal a common sequence pattern among the epitopes allowing for KIR2DL2 binding, nor did KIR2DL2-engaging epitopes meet previously postulated requirements [10] . Distinct KIRengaging sequence requirements might not exist, as every HLA-epitope interaction is complex and provides unique amino acid size and/or charge requirements to engage KIR2DL2.
HIV-1 sequences within epitopes that engage KIR2DL2 may represent sequences selected to engage this inhibitory KIR in individuals expressing the corresponding HLA/KIR compound genotypes, leading to reduction of NK cell activation as we show for OLP11 (Gag144-152) and OLP30 (Gag163-171) in vitro. Recent studies have suggested that HIV-1 might adapt to NK cell mediated immune pressure, as there are several amino acid polymorphisms within HIV-1 that are significantly associated with the expression of specific KIRs on a population level [44] . The p24 Gag peptide OLP163 (Gag295-304, DYVDRFFKTL) represents an interesting HLA-C Ã 03:04-restricted epitope in this regard, given that previous studies [42] have demonstrated several mutations selected for in the ninth amino acid position of this epitope in HLA-C Ã 03þ individuals. Here, we show that these variants also allow for binding of the inhibitory NK cell receptor KIR2DL2, in particular, the T303V variant of this epitope (OLP163-V, DYVDRFFKVL), which did not mediate escape from epitope-specific CD8 þ T cells in the previous study by Honeyborne et al. [42] . Selection of these escape variants might therefore represent a potential mechanism by which HIV-1 evades NK cell mediated killing.
In summary, the present study demonstrates that sequence variations in HLA-C Ã 03:04-presented HIV-1 epitopes can promote or abrogate KIR2DL2 binding to HLA-C Ã 03:04, and that minor circulating variants of HLA-C Ã 03:04-binding epitopes can reconstitute the binding of this inhibitory NK cell receptor and affect primary NK cell function. Further studies will be required to determine whether these sequence polymorphisms are selected for during infection and whether they can allow HIV-1 to evade recognition by KIR2DL2þ NK cells.
